A limitation of our study is the reduced sample size in the HER2 positive tumor types (HR+/HER2+: n = 68, HR-/HER2+: n = 43), which might hamper the detection of a differential expression of GCDFP-15 or a prognostic impact of GCDFP-15 expression within those tumor types. This evidence concerns the gene PIP and neoplasm.